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Abstract
The highly immunogenic human tumor antigen NY-ESO-1 (ESO) is a target of choice for anti-cancer immune therapy. In this
study, we assessed spontaneous antibody (Ab) responses to ESO in a large cohort of patients with primary breast cancer
(BC) and addressed the correlation between the presence of anti-ESO Ab, the expression of ESO in the tumors and their
characteristics. We found detectable Ab responses to ESO in 1% of the patients. Tumors from patients with circulating Ab to
ESO exhibited common characteristics, being mainly hormone receptor (HR)
2 invasive ductal carcinomas of high grade,
including both HER2
2 and HER2
+ tumors. In line with these results, we detected ESO expression in 20% of primary HR
2 BC,
including both ESO Ab
+ and Ab
2 patients, but not in HR
+ BC. Interestingly, whereas expression levels in ESO
+ BC were not
significantly different between ESO Ab
+ and Ab
2 patients, the former had, in average, significantly higher numbers of
tumor-infiltrated lymph nodes, indicating that lymph node invasion may be required for the development of spontaneous
anti-tumor immune responses. Thus, the presence of ESO Ab identifies a tumor subtype of HR
2 (HER2
2 or HER2
+) primary
BC with frequent ESO expression and, together with the assessment of antigen expression in the tumor, may be
instrumental for the selection of patients for whom ESO-based immunotherapy may complement standard therapy.
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Introduction
Human breast cancers (BC) are highly heterogeneous with
respect to their biologic and clinical profiles. Currently, clinical
management relies on known prognostic factors, including
hormone receptor (HR) and HER2 status. Evaluation of the
expression of these factors is valuable for predicting responsiveness
to therapies that specifically target them [1,2,3]. Despite
treatment, however, a number of patients progress and in patients
who do not express these markers, therapeutic options remain
limited.
Cancer-testis (CT) antigens are encoded by a group of genes
expressed in human germ line cells, silenced in somatic cells in
normal adult tissues, and aberrantly re-expressed in cancerous
cells in tumors of different histological types [4]. About half of the
known genes encoding CT antigens are located in the X-
chromosome (CT-X), and together represent approximately 10%
of all genes in the X [5]. Because of their highly tumor-specific
expression, CT antigens are excellent targets of anti-tumor
immune responses. For several group members, specific immune
responses can develop spontaneously in some cancer patients
bearing antigen-expressing tumors. One of the most studied family
members, NY-ESO-1 (ESO), is remarkably immunogenic, elicit-
ing spontaneous antibody (Ab) and T cell responses [6,7]. Because
of its high immunogenicity, ESO has been selected among the
high priority candidates for the development of generic anti-cancer
vaccines [8]. The development is promising, with some formula-
tions showing high immunogenicity in cancer patients [9]. Clinical
efficacy of ESO-based vaccination, however, remains to be
demonstrated, through upcoming clinical trials targeting specific
patient populations. Other approaches targeting ESO-expressing
tumors through adoptive transfer therapy are also being developed
and have recently yielded the first evidence of clinical efficacy [10].
Because of the potential of ESO for immunotherapy, identification
of BC patients with spontaneous immune responses to the antigen
could be instrumental for the selection of the patients who could
benefit from ESO-based immunotherapy. Here we show that the
presence of ESO Ab identifies a subtype of primary BC with
frequent ESO expression and, together with the assessment of
antigen expression in the tumor, is instrumental for the selection of
patients for whom ESO-based immunotherapy may complement
standard therapy.
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Assessment of ESO-specific Ab in patients with primary
BC
We assessed the presence of circulating ESO-specific Ab in a
cohort of 1374 patients with primary BC seen at our institution
from 1999 to 2008. ESO Ab were assessed by ELISA in sera taken
at the time of first surgery, using a recombinant ESO protein
(rESO) produced by expression in E. coli, as described previously
[11]. Samples from patients and control healthy donors were
screened on rESO-coated microplates and on control plates with
no antigen. Data obtained are shown in Figure 1A. Samples that
scored as positive in this first screening were further assessed with
an unrelated control protein similarly produced in E. coli, to
eliminate sera that non-specifically reacted with bacterial contam-
inants in the preparation (Figure 1B). Following this analysis, 12
patients (1%) were confirmed as positive for serological IgG
responses to ESO (Ab
+) and were further assessed in a titration
assay to determine antibody titers (Figure 1C). The latter varied
from 1:150 to 1:22000 (average 1:2800).
ESO expression in primary BC tumors from ESO Ab
+
patients and correlation with HR and HER2 status
The characteristics of the ESO Ab
+ patients and of the
corresponding tumors are reported in Table 1 (upper part). For
9 of them cryopreserved tumor tissue was available. We assessed
ESO expression in these samples by semi-quantitative PCR using
previously validated primers (Figure 2A). ESO expression was
further confirmed and quantified by qPCR (Figure 2B). Tumor
lines and healthy tissues were used as internal controls (Figure 2
and Supporting Figure S1). In support of the results of the
serological analysis, we found ESO expression in 8 of the 9 tumors.
Tumors from ESO Ab
+ patients were mostly invasive ductal
carcinomas (IDC), 1 was diagnosed as medullary breast cancer
(MBC) and 2 as lymph node metastases with unknown primary.
Tumors were of high grade, estrogen receptor (ER)
2 and
progesterone receptor (PR)
2. Three of them over-expressed
HER2. Five of the patients had a family history of BC, 4 of them
had other cancers and 2 of them had deceased at the time of
analysis. It is noteworthy that the only patient for whom we could
not detect ESO expression in the breast tumor (that at variance
with the others was low grade, ER
+) was diagnosed with malignant
melanoma, that frequently expresses ESO, a few months after the
diagnosis of BC.
Expression of ESO in ER
2 and ER
+ BC
The correlation between ESO expression and the ER status
found for ESO Ab
+ patients prompted us to extend the
assessment of ESO expression to a larger group of ER
2 tumors
and a similar group of ER
+ tumors from patients in the cohort.
Samples were assessed by semi-quantitative PCR and qPCR
(Figure 3A and 3B). We found significant ESO expression in 18
(20%) of ER
2 BC including the 8 patients previously identified
through serological analysis and 10 additional patients without
detectable ESO Ab. In contrast, we did not find significant levels
of ESO expression in the ER
+ tumors. The characteristics of
ESO Ab
2 patients with detectable ESO expression and of the
corresponding tumors are reported in Table 1 (lower part).
Similar to the tumors from ESO Ab
+ patients, the majority of the
tumors from these patients were high grade and PR
2. The large
majority was IDC, with 1 diagnosed as MBC and 1 as basal-like
cancer (BLC). One of the tumors over-expressed HER2. Three of
the patients had a family history of breast cancer, none of them
had other tumors and 2 of them had deceased at the time of
analysis. Thus, ESO-expressing Ab
2 patients had characteristics
similar to those of the ESO Ab
+ group. It is noteworthy that the
expression levels of ESO in tumors from ESO Ab
+ patients were
not significantly different from those found in ESO-expressing
tumors from ESO Ab
2 patients (Figure 3C). We found no
significant difference in tumor size between the 2 groups.
Interestingly, however, the number of tumor-invaded lymph
nodes was, in average, significantly higher in Ab
+ patients than in
Ab
2 patients (Figure 3C).
To further address the relationship between the ER status of BC
tumors and ESO expression, we assessed ESO expression in 8 BC
tumor lines including 4 ER
2 and 4 ER
+ lines [12]. As shown in
Figure 4A, we found ESO expression in one of the ER
2 lines,
MDA-MB-157, but in none of the ER
+ lines. To address if
expression of ER directly affects ESO expression in BC tumors, we
transfected MDA-MB-157 cells with an ER-encoding plasmid
Figure 1. Assessment of circulating ESO-specific Ab in patients with primary BC. A. Sera from BC patients and control healthy donors (HD)
were screened by ELISA at a serum dilution of 1:100 on rESO-coated plates and on control plates with no antigen. Samples were considered positive
when the optical density (OD) value obtained on rESO-coated plates was higher than the mean+6xSD of OD values obtained with sera from HD on
rESO-coated plates. B. Samples that scored positive in A were assessed at a dilution of 1:400 on plates coated with rESO or rMelan-A. Samples were
confirmed as ESO Ab
+ if the OD value obtained on rESO-coated plates was both higher than the mean+6xSD of OD values obtained on rMelan-A-
coated plates for all patients and 3 folds higher than the OD value obtained for the same serum on rMelan-A-coated plates. C. Serial dilutions of ESO
Ab
+ sera were assessed on rESO (solid lines) and rMelan-A (dotted lines) coated plates and serum titer was calculated as the serum dilution yielding
50% of maximal OD on rESO-coated plates.
doi:10.1371/journal.pone.0021129.g001
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MB-157 cells after transfection but no significant effect on ESO
expression was observed (Figure 4B).
Expression of ESO in triple negative breast cancers
Patients with ER
2/PR
2/HER2
2 BC tumors (called triple
negative, TN) have poor prognosis and limited therapeutic
options. To further validate the ESO expression data obtained
in the first cohort, we assessed a separate cohort of 42 TN high-
grade IDC BC tumors collected from 1999 to 2003 at the Italian
National Cancer Institute (Aviano, Italy). For these tumors,
paraffin-embedded blocks were available for analysis and were
assessed for expression of ESO protein by IHC. Examples of the
results obtained are shown in Figure 5 and data obtained for all
tumors are summarized in Supporting Table S1. We found
detectable ESO expression in 10 (24%) of the samples. Both the
proportion of BC cells expressing ESO and the intensity of staining
were variable among samples, in line with previous findings in
tumors of different histological types [13,14]. TN BC encompass
BLC, that are believed to originate from basal stem precursors
[15]. To explore a possible correlation between ESO expression in
TN tumors and BLC, we assessed the expression of several basal-
like associated markers, including epithelial growth factor receptor
(EGFR), p63, cytokeratine (CK)5 and CK14 (Supporting Table
S1). As expected, we found a frequent expression of these markers
in TN tumors. We failed, however, to find a correlation between
ESO expression and any of the markers (Supporting Figure S2).
Thus expression of ESO, although frequent in TN tumors, is not
restricted to the basal-like type, in agreement with the presence of
HER2
+ tumors, that are distinct from basal-like tumors, among
ESO-expressing cases (Table 1).
Discussion
Clinical management of primary BC mainly rests on the
assessment of HR and HER2 expression along with tumor grade.
Patients bearing HR-expressing tumors are eligible, in addition to
chemotherapy, for hormonotherapy, and those with HER2 over-
expressing tumors to treatment with herceptin (trastuzumab). With
the aim of developing improved approaches for the treatment of
Table 1. BC patients with detectable ESO Ab and/or ESO expression and characteristics of the corresponding tumors.
Patient
ESO
Ab
ESO
exp
* ER
{ PR
{ HER2
{ Age
1 SBR
I Histological type Other tumors Survival
11 Relapse
Family
history
##
NB1/78 + na 222 26 III IDC
{{ - D Liver +
NB1/11 ++22+ 61 III IDC Meningioma A - +
NB5/35 ++22nd 52 up
** up - A - 2
NB1/27 ++222 59 III IDC - A - 2
NB15/55 + na 222 48 up up Cervical A - +
NB1/41 ++222 61 III IDC - A Skin, LN +
NB1/4 ++222 57 III IDC - A - 2
NB14/73 + na 22+ 68 III IDC - A - 2
NB1/17 ++222 37 III IDC - D LN +
NB7/6 ++22+ 65 III IDC Spinocellular A - 2
NB14/56 ++222 66 III MBC
{{ -A - 2
NB2/67 + 2 + 22 71 I IDC Melanoma A - 2
NB1/8 2 + 222 65 II IDC - A - +
NB1/13 2 + 222 48 III IDC - A - 2
NB1/15 2 + 222 56 II IDC - D Pleural, skin,
LN
+
NB1/26 2 + 222 65 III IDC - A - 2
NB1/37 2 + 22+ 83 III ILC
# -A - 2
NB1/38 2 + 222 55 III Basal-like - A - 2
NB1/47 2 + 222 58 III IDC - A - 2
NB1/80 2 + 222 74 III IDC - D Skin 2
NB1/85 2 + 222 42 III MBC - A - +
NB14/78 2 + 222 62 III IDC - A - 2
*ESO mRNA expression in frozen tumor specimens was assessed by RT-PCR. na, not available.
{ER and PR expression was assessed by IHC staining of paraffin-embedded tumor specimens.
{HER2 was assessed by IHC staining in paraffin-embedded tumor specimens and gene amplification was confirmed by FISH analysis. nd, not done.
1Age at diagnosis.
ISBR, Scarff-Bloom-Richardson tumor grade.
**Lymph node metastasis with unknown primary (up).
{{IDC, invasive ductal carcinoma.
{{MBC, medullary breast cancer.
#ILC, invasive lobular carcinoma.
11D, dead; A, alive.
##Known family history of breast cancer.
doi:10.1371/journal.pone.0021129.t001
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distinguished based on their gene-expression profiles. The main
classification [15] proposes five classes: normal-like; Luminal-A,
mostly ER
+, low grade; Luminal-B, mostly ER
+/low, high grade;
BLC, mostly ER
2,P R
2 and HER2
2 (TN); and HER2
+ BC. The
molecular types also correlate with prognosis and response to
therapy. Namely, whereas Luminal-A tumors are generally
indolent and sensitive to hormonotherapy, Luminal-B tumors
and ER
+ HER2
+ tumors are less responsive. Both HER2
+ tumors
and BLC are aggressive, with HER2
+ tumors being selectively
sensitive to trastuzumab and both HER2
+ tumors and BLC
possibly more sensitive to preoperative chemotherapy [16].
Although the immediate added clinical value of the molecular
classification is limited by its correlation with HR, HER2 status
and tumor grade, the demonstration of differential gene expression
profiles in these tumor types is providing a broader view of their
phenotype that could reveal new type-specific therapeutic targets.
The clinical efficacy of trastuzumab in patients with HER2
over-expressing tumors has clearly demonstrated the possibility to
impact on disease progression through immunotherapy and
encourages the development of anti-cancer vaccines in breast
cancer, provided that appropriate target tumor antigens and
patient groups are identified. In this study, we have assessed
spontaneous Ab responses to one of the most immunogenic CT
antigens, ESO, in a large cohort of patients with primary BC. This
is, in our knowledge, the first systematic assessment of spontaneous
immune responses to a member of the CT antigens group in
primary BC. The results obtained provide important cues for
ESO-based immunotherapy in these patients. We identified a
small group of patients (1%) with detectable spontaneous Ab
responses to ESO. Tumors from patients with circulating Ab to
ESO exhibited common characteristics, being mainly HR
2 IDC
of high grade, including HER2
2 and HER2
+ tumors. In line with
these results, we detected ESO expression in 20% of primary HR
2
BC from both ESO Ab
+ and Ab
2 patients, but not in HR
+ BC.
Expression levels in ESO
+ BC were not significantly different
between ESO Ab
+ and Ab
2 patients, but the former had, in
average, significantly higher numbers of tumor-infiltrated lymph
nodes. Thus, the presence of ESO Ab identifies a subtype of HR
2
primary BC (HER2
+ or HER2
2) with frequent ESO expression.
The molecular basis of the relationship between the HR status
of BC tumors and the expression of ESO is unknown. By
transfecting an ER
2 ESO
+ BC line with an ER-encoding plasmid
we failed to detect any significant alteration of ESO expression,
suggesting that the correlation between the HR status of BC and
the expression of ESO may reflect a particular molecular subtype
of the tumor rather than a direct effect of HR on ESO expression.
We confirmed the frequent expression of ESO at the protein
level by IHC in a separate cohort of TN tumors. Interestingly, TN
BLC, that are believed to originate from basal stem precursors, are
characterized by frequent dysfunction of the BRCA1 pathway,
which is important in DNA repair, activation of cell cycle
checkpoints and maintenance of chromosomal stability, including
X chromosome inactivation (Xi) [17,18]. It is therefore tempting
to propose the existence of a possible link between CT-X
Figure 3. Assessment of ESO expression in ER
2 and ER
+ BC
tumors. A and B. ESO expression in cryopreserved ER
2 and ER
+ BC
tumors was assessed by semi-quantitative PCR (A) and qPCR (B). C. The
level of ESO expression in the tumor as assessed by qPCR (left panel,
mean 6 SD), the size of the primary tumor at diagnosis (middle panel,
mean 6 SD) and the number of tumor-invaded lymph nodes (right
panel, mean 6 SD) are shown for ESO Ab
+ (n=8) and ESO Ab
2 (n=10)
patients with ESO-expressing tumors. Statistical analyses were per-
formed using a two-tailed t-test.
doi:10.1371/journal.pone.0021129.g003
Figure 2. Assessment of ESO expression in BC tumors from ESO
Ab
+ patients. ESO expression in cryopreserved BC tumors from ESO
Ab
+ patients was assessed by semi-quantitative PCR (A) and qPCR (B)
using specific primers and ESO
+ (SK-MEL-37, Me252) and ESO
2 (NA8,
SK-MEL-23, Me290) tumor cell lines as internal controls.
doi:10.1371/journal.pone.0021129.g002
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are complicated by our finding that CT-X expression is not limited
to the TN BLC group, as a fraction of CT-X expressing HR
2
tumors in this study were positive for HER2, whose over-
expression identifies a subgroup of BC with molecular character-
istics distinct from BLC [15].
The finding that patients with primary BC bearing sometimes
relatively small ESO-expressing tumors can mount significant
serological responses to ESO is somewhat unexpected, with
respect to previous studies that have reported serological responses
to ESO in patients bearing significant tumor load, that in some
instances become ESO Ab
2 after removal of the tumor [19].
These results could imply a particularly high immunogenicity of
BC or/and that the primary lesion may not represent the actual
total tumor mass present at diagnosis in these patients.
Interestingly however, we found that the presence of ESO Ab in
patients with ESO-expressing BC correlates with the presence of
the tumor in the local lymph nodes, suggesting that the latter may
be required for the development of spontaneous anti-tumor
response. Another important implication of our findings is that
ESO may represent a highly specific marker for the detection of
tumor cells outside the primary tumor site, i.e. in the circulation,
lymph nodes or bone marrow.
In conclusion, the results of our study indicate that the presence of
circulating antibodies to ESO identifies a group of HR
2 BC with
frequent ESO expression and, together withthe assessment of antigen
expression in the tumor, may be instrumental for the selection of
patients who may benefit from recently developed highly immuno-
genic ESO-based vaccines [9]. Anti-cancer vaccination as a
complement for standard therapy is particularly attractive in this
group of patients, including those bearing TN tumors, for whom
therapeutic options are limited, and for patients with HER2
+ER
2
tumors where it may be combined with trastuzumab.
Materials and Methods
Patients, sera, tumors, normal tissues and tumor cell lines
Sera and surgical tumor specimens from breast cancer patients
seen at CLCC Rene ´ Gauducheau (Nantes-Saint Herblain, France)
at the time of first surgery, as well as sera from healthy donors
(HD), were collected, upon written informed consent and approval
by the Comite ´ de Protection des Personnes Ouest IV – Nantes,
France, and cryopreserved. Specimens of triple negative tumors
were obtained at the Italian National Cancer Institute (Aviano,
Italy), upon written informed consent and approval by the Ethics
Committee of the Centro di Riferimento Oncologico, Aviano,
Italy, and were fixed in formalin and embedded in paraffin. Total
RNA from human normal tissues was purchased from Ambion
Inc. Tumor cell lines were maintained in culture in complete
DMEM medium (Gibco, Invitrogen, Cergy Pontoise, France)
supplemented with 10% fetal calf serum.
Detection of circulating ESO-specific antibodies
Antibody (Ab) responses to ESO were assessed by ELISA, as
previously described [9,11], using recombinant ESO protein
(rESO) or control recombinant Melan-A protein (rMelan-A)
produced in E. coli [20]. Briefly, rESO-, rMelan-A- or un-coated
plates were incubated with the indicated dilutions of patients or
HD sera, washed, incubated with alkaline phosphatase-coupled
Figure 5. Expression of ESO in triple negative BC. Expression was
assessed by IHC staining of paraffin-embedded tumors using the ESO-
specific mAb E978. Tumors were scored based on the percentage of
positive cells (-, 0-rare; 1, ,10%; 2, 10–25%; 3, 25–50%; 4, .50%) and
the staining intensity (A, faint; B, moderate; C, strong). Testis (positive
control, a), normal breast (negative control, b) and examples of triple
negative tumors scored as negative (c), 4B (d), 3C (e) and 4C (f) are
shown. Magnification: 620.
doi:10.1371/journal.pone.0021129.g005
Figure 4. Assessment of ESO expression in BC lines. A.E R( ESR1)
and ESO expression in the indicated BC lines was assessed by qPCR. B.
MDA-MB-157 cells were transfected with a plasmid encoding the full
length ER (pESR1) or were mock transfected and ER and ESO expression
was assessed 24, 48 and 72 h post-transfection by qPCR.
doi:10.1371/journal.pone.0021129.g004
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CliniSciences SA, Montrouge, France) and the reaction was
revealed using the Attophose substrate (Promega, Charbonnie `res-
les-Bains, France).
Assessment of ESO expression by semi-quantitative and
quantitative PCR
Total RNA was prepared from frozen tumor specimens and
from tumor cell lines using the NucleoSpinH RNA II kit
(Macherey-Nagel, Hoerdt, France). Where indicated, MDA-MB-
157 cells (1610
6) were transfected with 1 mg of a recombinant
pCMV6-XL5 plasmid encoding the full length ER (pESR1,
OriGene, CliniSciences SA, Montrouge, France) or mock
transfected using the Cell Line Nucleofector kit V (Amaxa, Ko ¨ln,
Germany) and a Nucleofector II electroporation device (Amaxa),
according to the manufacturer’s instructions, and total RNA was
extracted 24, 48 and 72 h following transfection. cDNA synthesis
was performed using Promega Reverse Transcription System
A3500 (Promega). Semi-quantitative PCR was performed using
GoTaqH Flexi DNA Polymerase (Promega). cDNA integrity was
tested by amplification of b-actin mRNA and ESO mRNA
expression was assessed using the following primers: forward
primer: 59-ATGGATGCTGCAGATGCGG-39 and reverse prim-
er: 59-GGCTTAGCGCCTCTGCCCTG-39. Quantitative PCR
(qPCR) was performed with a TaqMan assay and an ABI 7000
system (Applied Biosystems, Courtaboeuf, France) using assays-on-
Demand Gene Expression probes for ESO (Hs00265824_m1,
Applied Biosystems) and ESR1 (Hs00174860_m1, Applied Biosys-
tems) and previously described GAPDH-specific Taqman probe
and primers [21]. Relative mRNA expression was calculated as
2
(Ct GAPDH - Ct Test gene).
Assessment of ESO and basal-like markers expression in
tumor samples by IHC
5-mm cuts of standard formalin-fixed, paraffin-embedded tissue
specimens were applied to IHC slides, heated at 60uC and
deparaffinized. Following antigen retrieval, samples were stained
using mAb specific for ESO (E978, Invitrogen, Milano, Italy),
CK5 (XM26, Novocastra, Menarini Florence, Italy), CK14
(LL002, Ventana Medical Systems, Tucson, Arizona), EGFR
(3C6, Ventana Medical Systems) and p63 (4A4, Dako, Milano,
Italy) and revealed with the Envision Plus system with DAB
(Dako). Counterstaining was performed with a hematoxylin
solution. Tumors were scored based on the percentage of positive
cells (-, 0-rare; 1, ,10%; 2, 10–25%; 3, 25–50%; 4, .50%) and
the staining intensity (A, faint; B, moderate; C, strong).
Supporting Information
Figure S1 Assessment of ESO expression in normal
tissues. ESO expression was assessed by semi-quantitative PCR
(A) and qPCR (B) following reverse transcription of mRNA from a
panel of normal tissues and was used to determine the cut-off
between positive and negative tumor samples.
(TIF)
Figure S2 Expression of ESO and of basal-like carcino-
ma associated markers in triple negative BC. Expression
of ESO, CK5, CK14, EGFR and p63 was assessed by IHC
staining of paraffin-embedded tumors from a cohort of 42 patients
with triple negative BC (Supporting Table S1). The percentage of
tumors expressing ESO within the entire cohort and of tumors
expressing the indicated basal-like associated markers within the
entire cohort or among ESO
+ tumors are shown. na, non
applicable.
(TIF)
Table S1 Expression of ESO and of basal-like carcino-
ma associated markers in a cohort of triple negative
breast cancers.
(DOC)
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